Kane Biotech (CVE:KNE) Hits New 1-Year Low – Here’s What Happened

Kane Biotech Inc. (CVE:KNE) shares hit a new 52-week low on Tuesday . The company traded as low as C$0.02 and last traded at C$0.02, with a volume of 45000 shares trading hands. The stock had previously closed at C$0.03.

Kane Biotech Trading Up 50.0%

The company has a current ratio of 0.45, a quick ratio of 0.39 and a debt-to-equity ratio of -135.17. The stock has a market capitalization of C$6.15 million, a PE ratio of -3.00 and a beta of 1.05. The stock has a 50 day moving average price of C$0.03 and a 200-day moving average price of C$0.03.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.